童卫华

【摘要】 目的：探讨胸腺法新对初治涂阳肺结核患者的临床应用价值。方法：选取2018年1月-2020年6月德兴市人民医院收治的82例初治涂阳肺结核患者为研究对象，随机分为两组，每组41例。对照组采取常规抗结核治疗，研究组则采用常规抗结核药物与胸腺法新相结合。比较两组治疗6个月后的疗效和临床症状缓解所需时间及T细胞亚群水平和治疗后1、3、6个月痰菌阴转情况。结果：研究组总有效率、治疗后3、6个月痰菌阴转率及各T细胞亚群指标均高于对照组（P<0.05），各症状缓解时间均短于对照组（P<0.05）。结论：对初治涂阳肺结核患者采用胸腺法新治疗，其效果较好，痰菌转阴率得到提升，有助于缩短症状缓解时间，改善机体免疫功能，值得临床推广应用。

【关键词】 胸腺法新 涂阳 肺结核 痰菌阴转

Effect of Thymalfasin on Clinical Efficacy and Negative Conversion of Sputum Bacteria in Newly-Treated Smear-positive Tuberculosis Patients/TONG Weihua. //Medical Innovation of China， 2021， 18（12）： -158

[Abstract] Objective： To explore the clinical application value of Thymalfasin for newly-treated smear-positive pulmonary tuberculosis patients. Method： A total of 82 newly-treated smear-positive pulmonary tuberculosis patients accepted in Jiangxi Dexing Hospital from January 2018 to June 2020 were selected as the research objects， and they were randomly divided in two groups， 41 cases in each group. The control group was given conventional anti-tuberculosis treatment， and the study group was given anti-tuberculosis drugs combined with Thymalfasin. The curative effect， the time needed for clinical symptom relief， the level of T cell subsets after 6 months for treatment and the negative conversion of sputum bacteria at 1， 3 and 6 months after treatment were compared between the two groups. Result： The total curative effect negative conversion of sputum bacteria rate and T cell subsets in the study group were higher than those of the control group （P<0.05）， and the time needed for clinical symptom relief in the study group was shorter than that of the control group （P<0.05）. Conclusion： The newly-treated smear-positive pulmonary tuberculosis with Thymalfasin has a good effect， and the negative conversion rate of sputum bacteria is improved， which is helpful to shorten the symptom relief time and improve the immune function of the body， and is worthy of clinical promotion and application.

[Key words] Thymalfasin Smear-positive Tuberculosis Negative conversion of sputum bacteria

First-authors address： Dexing Hospital， Dexing 334200， China

doi：10.3969/j.issn.1674-4985.2021.12.037

臨床中，结核病主要是由于结核分枝杆菌引发的一种慢性传染性疾病，能够导致机体内多个脏器出现损伤，且以肺部病变较为常见[1]。机体在感染肺结核之后的前期并不一定发病，但当存在自身感染或者抵抗力降低时则会导致该疾病发作[2]。结核病的流行性及传染性均较高，但若采取及时、有效的治疗方案则能够提升该疾病的治愈率，促进患者预后[3]。初治涂阳肺结核主要是指经直接涂片镜检存在2次阳性的初诊肺结核，对于该类患者及时采取标准化的短期治疗，能够获得较为理想的治疗效果[4]。在以往的临床治疗中主要以抗结核药物为主，但随着临床实践显示，该药物的临床疗效并不理想，且患者预后较慢，不利于临床推广应用[5]。研究发现，采用免疫调节剂对肺结核患者进行辅助治疗能够促进机体免疫水平的提升，使其体内细菌得到快速清除[6]。……